Unmet needs in cystic fibrosis: the next steps in improving outcomes

Natalie E West, Patrick A. Flume

Research output: Contribution to journalReview article

Abstract

Introduction: Cystic fibrosis (CF) outcomes and survival have improved over the last century primarily due to advancements in antibiotics, nutritional, and pulmonary therapies. Reviewed here are the significant unmet needs that exist for individuals with CF. Areas covered: With the recent development of medications that address the underlying defect in the CF protein, there is hope that there will be continued improvement in CF outcomes. However, there remains a need to prevent or stop progression of CF-related complications, as the CF protein is important to several body systems. As end stage lung disease is the primary cause of mortality in CF, a need exists for advancements in pulmonary therapies to reduce time burden, identification of best practices for the treatment of pulmonary exacerbations, further development of anti-infective and anti-inflammatory therapies, and appropriately timed referral for lung transplantation at end-stage lung disease. Extra-pulmonary complications are increasingly recognized and better understanding of such problems as CF related liver disease is needed. Expert commentary: While CFTR modulators are available for the majority of CF patients, there remains a need for effective therapies to address infection, inflammation, irreversible lung disease, and extrapulmonary complications of CF.

Original languageEnglish (US)
Pages (from-to)585-593
Number of pages9
JournalExpert Review of Respiratory Medicine
Volume12
Issue number7
DOIs
StatePublished - Jul 3 2018

Fingerprint

Cystic Fibrosis
Lung Diseases
Lung
Therapeutics
Lung Transplantation
Practice Guidelines
Liver Diseases
Proteins
Anti-Inflammatory Agents
Referral and Consultation
Anti-Bacterial Agents
Inflammation
Survival
Mortality
Infection

Keywords

  • Cystic fibrosis
  • cystic fibrosis-related liver disease
  • inflammation
  • ivacaftor
  • lumacaftor
  • lung transplant
  • pancreatic insufficiency
  • pulmonary exacerbations
  • tezacaftor
  • unmet needs

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Unmet needs in cystic fibrosis : the next steps in improving outcomes. / West, Natalie E; Flume, Patrick A.

In: Expert Review of Respiratory Medicine, Vol. 12, No. 7, 03.07.2018, p. 585-593.

Research output: Contribution to journalReview article

@article{e2cfe5d677c041a09808c1645d5d843c,
title = "Unmet needs in cystic fibrosis: the next steps in improving outcomes",
abstract = "Introduction: Cystic fibrosis (CF) outcomes and survival have improved over the last century primarily due to advancements in antibiotics, nutritional, and pulmonary therapies. Reviewed here are the significant unmet needs that exist for individuals with CF. Areas covered: With the recent development of medications that address the underlying defect in the CF protein, there is hope that there will be continued improvement in CF outcomes. However, there remains a need to prevent or stop progression of CF-related complications, as the CF protein is important to several body systems. As end stage lung disease is the primary cause of mortality in CF, a need exists for advancements in pulmonary therapies to reduce time burden, identification of best practices for the treatment of pulmonary exacerbations, further development of anti-infective and anti-inflammatory therapies, and appropriately timed referral for lung transplantation at end-stage lung disease. Extra-pulmonary complications are increasingly recognized and better understanding of such problems as CF related liver disease is needed. Expert commentary: While CFTR modulators are available for the majority of CF patients, there remains a need for effective therapies to address infection, inflammation, irreversible lung disease, and extrapulmonary complications of CF.",
keywords = "Cystic fibrosis, cystic fibrosis-related liver disease, inflammation, ivacaftor, lumacaftor, lung transplant, pancreatic insufficiency, pulmonary exacerbations, tezacaftor, unmet needs",
author = "West, {Natalie E} and Flume, {Patrick A.}",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/17476348.2018.1483723",
language = "English (US)",
volume = "12",
pages = "585--593",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Unmet needs in cystic fibrosis

T2 - the next steps in improving outcomes

AU - West, Natalie E

AU - Flume, Patrick A.

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Cystic fibrosis (CF) outcomes and survival have improved over the last century primarily due to advancements in antibiotics, nutritional, and pulmonary therapies. Reviewed here are the significant unmet needs that exist for individuals with CF. Areas covered: With the recent development of medications that address the underlying defect in the CF protein, there is hope that there will be continued improvement in CF outcomes. However, there remains a need to prevent or stop progression of CF-related complications, as the CF protein is important to several body systems. As end stage lung disease is the primary cause of mortality in CF, a need exists for advancements in pulmonary therapies to reduce time burden, identification of best practices for the treatment of pulmonary exacerbations, further development of anti-infective and anti-inflammatory therapies, and appropriately timed referral for lung transplantation at end-stage lung disease. Extra-pulmonary complications are increasingly recognized and better understanding of such problems as CF related liver disease is needed. Expert commentary: While CFTR modulators are available for the majority of CF patients, there remains a need for effective therapies to address infection, inflammation, irreversible lung disease, and extrapulmonary complications of CF.

AB - Introduction: Cystic fibrosis (CF) outcomes and survival have improved over the last century primarily due to advancements in antibiotics, nutritional, and pulmonary therapies. Reviewed here are the significant unmet needs that exist for individuals with CF. Areas covered: With the recent development of medications that address the underlying defect in the CF protein, there is hope that there will be continued improvement in CF outcomes. However, there remains a need to prevent or stop progression of CF-related complications, as the CF protein is important to several body systems. As end stage lung disease is the primary cause of mortality in CF, a need exists for advancements in pulmonary therapies to reduce time burden, identification of best practices for the treatment of pulmonary exacerbations, further development of anti-infective and anti-inflammatory therapies, and appropriately timed referral for lung transplantation at end-stage lung disease. Extra-pulmonary complications are increasingly recognized and better understanding of such problems as CF related liver disease is needed. Expert commentary: While CFTR modulators are available for the majority of CF patients, there remains a need for effective therapies to address infection, inflammation, irreversible lung disease, and extrapulmonary complications of CF.

KW - Cystic fibrosis

KW - cystic fibrosis-related liver disease

KW - inflammation

KW - ivacaftor

KW - lumacaftor

KW - lung transplant

KW - pancreatic insufficiency

KW - pulmonary exacerbations

KW - tezacaftor

KW - unmet needs

UR - http://www.scopus.com/inward/record.url?scp=85049046507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049046507&partnerID=8YFLogxK

U2 - 10.1080/17476348.2018.1483723

DO - 10.1080/17476348.2018.1483723

M3 - Review article

C2 - 29855230

AN - SCOPUS:85049046507

VL - 12

SP - 585

EP - 593

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 7

ER -